Bristol Myers Squibb Company $BMY Shares Sold by Meyer Handelman Co.

Meyer Handelman Co. lessened its position in Bristol Myers Squibb Company (NYSE:BMY) by 8.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 435,881 shares of the biopharmaceutical company’s stock after selling 39,637 shares during the period. Meyer Handelman Co.’s holdings in Bristol Myers Squibb were worth $23,511,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Vanguard Group Inc. grew its stake in Bristol Myers Squibb by 0.5% in the 3rd quarter. Vanguard Group Inc. now owns 195,984,009 shares of the biopharmaceutical company’s stock worth $8,838,879,000 after acquiring an additional 1,058,803 shares during the period. State Street Corp boosted its holdings in shares of Bristol Myers Squibb by 2.0% during the third quarter. State Street Corp now owns 96,595,232 shares of the biopharmaceutical company’s stock worth $4,356,445,000 after purchasing an additional 1,855,238 shares during the last quarter. Ameriprise Financial Inc. boosted its holdings in shares of Bristol Myers Squibb by 1.3% during the second quarter. Ameriprise Financial Inc. now owns 32,579,618 shares of the biopharmaceutical company’s stock worth $1,508,099,000 after purchasing an additional 432,158 shares during the last quarter. Independent Franchise Partners LLP grew its position in shares of Bristol Myers Squibb by 20.6% in the second quarter. Independent Franchise Partners LLP now owns 20,976,954 shares of the biopharmaceutical company’s stock valued at $971,023,000 after purchasing an additional 3,583,163 shares during the period. Finally, Invesco Ltd. increased its stake in Bristol Myers Squibb by 4.9% in the second quarter. Invesco Ltd. now owns 18,315,473 shares of the biopharmaceutical company’s stock valued at $847,823,000 after purchasing an additional 852,317 shares during the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Stock Performance

Shares of NYSE:BMY opened at $60.56 on Wednesday. The business has a 50-day moving average of $59.03 and a two-hundred day moving average of $52.45. The firm has a market capitalization of $123.65 billion, a PE ratio of 17.55, a P/E/G ratio of 0.17 and a beta of 0.26. The company has a debt-to-equity ratio of 2.32, a current ratio of 1.26 and a quick ratio of 1.14. Bristol Myers Squibb Company has a 12 month low of $42.52 and a 12 month high of $62.89.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing the consensus estimate of $1.65 by ($0.39). The firm had revenue of $12.50 billion during the quarter, compared to analyst estimates of $12.24 billion. Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The business’s revenue for the quarter was up 1.3% on a year-over-year basis. During the same period in the prior year, the firm earned $1.67 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, research analysts forecast that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd will be paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 4.2%. The ex-dividend date is Thursday, April 2nd. Bristol Myers Squibb’s payout ratio is currently 73.04%.

Analyst Ratings Changes

A number of analysts have issued reports on BMY shares. Bank of America raised Bristol Myers Squibb from a “neutral” rating to a “buy” rating and raised their price target for the stock from $52.00 to $61.00 in a research note on Monday, December 15th. Guggenheim reiterated a “buy” rating and set a $72.00 price objective (up from $62.00) on shares of Bristol Myers Squibb in a report on Friday, February 6th. Citigroup raised their target price on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a “neutral” rating in a research report on Friday, February 6th. Piper Sandler restated an “overweight” rating and issued a $75.00 target price (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, February 23rd. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Bristol Myers Squibb in a research report on Monday, March 23rd. Nine analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $61.41.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Phase‑3 adolescent win for Camzyos strengthens BMY’s cardiovascular franchise — the SCOUT‑HCM trial met its primary endpoint with robust efficacy and no new safety signals, supporting label expansion into younger patients and longer commercial runway for the drug. Camzyos Adolescent Trial Success Might Change The Case For Investing In Bristol-Myers Squibb (BMY)
• Positive Sentiment: FDA approval for a Hodgkin’s lymphoma combination therapy provides an immediate commercial lift and validates oncology execution — another approved product can help offset patent cliffs elsewhere. Bristol-Myers Squibb Gets FDA Approval for Hodgkin’s Lymphoma Treatment
• Positive Sentiment: Value/income investor interest — Ariel Global Fund re‑added BMY citing pipeline strength and attractive valuation, which could signal renewed institutional demand. Ariel Global Fund Re-Added Bristol-Myers Squibb Company (BMY) on Pipeline Strength and Attractive Valuation
• Neutral Sentiment: Analyst/education pieces (Zacks, Yahoo) highlight potential upside from earnings surprises using Earnings ESP and note BMY’s recent outperformance relative to its history, but these are directional signals rather than new fundamentals. Bristol Myers Squibb (BMY) Ascends But Remains Behind Market: Some Facts to Note
• Neutral Sentiment: Market reports project growth in oncology and kidney cancer drug markets through 2030, underlining long‑term addressable market tailwinds for BMY but not immediate revenue changes. Kidney Cancer Drugs Market to Grow by $2 Billion During 2026-2030
• Negative Sentiment: Some outlets note mixed analyst sentiment and questions around near‑term execution; investors should weigh recent approval and trial wins against prior earnings misses and heavy leverage on the balance sheet. Bristol-Myers Squibb (BMY) faces mixed analyst sentiment despite strong momentum in healthcare industry

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.